News

The phase 2b/3 clinical trial (NCT05683496) evaluated izokibep versus placebo in non-infectious, non-anterior uveitis.

Kaczmarek has a notable background of executive leadership and operational expertise in the gene therapy manufacturing industry.

USC is leading a research team aiming to better understand retinitis pigmentosa and inform future treatments.

This Week in Ophthalmology is a weekly video series highlighting some of the top articles and videos featured on the Ophthalmology Times website.

A study investigating the impact of socioeconomic status (SES) on open globe injury (OGI) found that lower SES, measured by the Social Vulnerability Index and Distressed Communities Index, correlates with younger age, non-accidental injuries, and poorer visual outcomes in OGI patients.

This interview comes at the Children's Hospital Los Angeles team celebrates its 100th retinal gene therapy procedure.

A confirmed diagnosis of familial exudative vitreoretinopathy aids in several aspects of patient management

The PFS is approved for treatment of neovascular age-related macular degeneration, diabetic macular oedema and macular oedema following retinal vein occlusion

The 14th annual Glaucoma 360 conference, co-founded by Adrienne Graves, PhD, and Andrew Iwach, MD, and hosted by Glaucoma Research Foundation, will be held from February 6-8, 2025, at the Westin St. Francis in San Francisco, California. The event will focus on the latest advancements in glaucoma care and encourage innovation and collaboration.

The aim of this program is to help advance junior clinical research scientists in their professional endeavors to cure retinal degenerative disease.

The joint project AMD-HALT, pairs Amarna’s SV40-derived gene delivery vector platform with Phenocell’s in vitro AMD disease model, which accurately mimics cellular interactions and microenvironment of the retina

Researchers conducted a retrospective study to assess serum inflammatory biomarkers in patients with different subtypes of diabetic macular edema (DME).

This study was published online in the journal Aging Cell and reveals how DNA damage compromises the retina’s function and accelerates vision loss.

Phenocell and Amarna Therapeutics were awarded the grant by Eureka’s Eurostars initiative, co-funded by the European Union

Tenpoint Therapeutics and Visus Therapeutics have merged to focus on aging-related ocular conditions, with key products including BRIMOCHOL PF for presbyopia and therapies for cataracts and geographic atrophy.

A retrospective study assessed elevated neutrophil-to-lymphocyte ratios and systemic immune-inflammation index levels in patients with different subtypes of DMO

In this series, experts in the field advise current residents and offer insight into how they can make the most of their time and experience moving forward with their careers.

The researchers conducted a retrospective study to assess serum inflammatory biomarkers in patients with different subtypes of diabetic macular edema (DME).

A look at the latest advances from flash photography to AI-driven OCT

VisiRose, a company formed in collaboration with Provectus Biopharmaceuticals and the University of Miami Miller School of Medicine’s Bascom Palmer Eye Institute, is advancing Rose Bengal Photodynamic Antimicrobial Therapy (RB PDAT), a non-invasive treatment for infectious keratitis, leveraging light-based technology and addressing antimicrobial resistance to improve outcomes for patients with severe eye infections globally.

Roche, Ainnova, and Salud 360 signed this alliance to improve access to vision screening in patients with uncontrolled diabetes.

ACELYRIN will not make any additional internal investment in developing izokibep.

EXG102 and EXG202 are investigational gene therapy candidates for wet age-related macular degeneration that are in development.

Research was based on results of a double-blinded, randomized, clinical trial performed between November 2017 and December 2022 in the strabismus clinic of Farabi Eye Hospital.

The research findings supported the hypothesis that a mild reduction in retinal contrast can slow myopia progression in young children

EXG102 and EXG202 are investigational gene therapy candidates for wet age-related macular degeneration that are in development.

Bausch + Lomb announced the acquisition of the ELIOS system, a laser-based technology that offers a new approach to treating glaucoma, particularly in conjunction with cataract surgery.